Legal Opinion of Hunan Qiyuan Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Hunan Nansheng Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders of Fangsheng Pharmaceutical
Announcement of Fangsheng Pharmaceutical on the receipt of a notice of acceptance of drug registration by its wholly-owned subsidiary
Fangsheng Pharmaceutical: Fangsheng Pharmaceutical 2024 Second Extraordinary General Meeting of Shareholders Meeting Information
Fangsheng Pharmaceutical 2024 Second Extraordinary General Meeting of Shareholders Meeting Data
Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Announcement of Fangsheng Pharmaceutical on signing a project repurchase agreement
Announcement on the progress of the transfer of 100% equity of a subsidiary of a wholly-owned subsidiary of Hunan Fangsheng Pharmaceutical
Announcement on the Investment and Establishment of a Holding Subsidiary and Related Transactions by Hunan Fangsheng Pharmaceutical.
Announcement from Hunan Fangsheng Pharmaceutical regarding its subsidiary's traditional Chinese medicine innovative drug research and development project receiving the drug clinical trial approval notification.
Announcement on the progress of the transfer of 100% equity of a subsidiary of a wholly-owned subsidiary of Hunan Fangsheng Pharmaceutical
Announcement of Resolutions of Fangsheng Pharmaceutical's 2023 Annual General Meeting of Shareholders
Legal Opinion of Hunan Qiyuan Law Firm on the 2023 Annual General Meeting of Shareholders of Hunan Nansheng Pharmaceutical Co., Ltd.
Fangsheng Pharmaceutical 2023 Annual General Meeting of Shareholders Meeting Materials
Fangsheng Pharmaceutical's announcement on preparation for asset impairment in 2023
Fangsheng Pharmaceutical Board Audit Committee's 2023 Performance Report
Fangsheng Pharmaceutical's 2023 Financial Results Report and 2024 Financial Budget Report
Report of the Audit Committee of the Board of Directors of Fangsheng Pharmaceutical on the performance of supervisory duties by accountants in the 2023 annual audit
Fangsheng Pharmaceutical's special report on the board of directors's self-inspection of the independence of independent directors in 2023
Fangsheng Pharmaceutical's announcement on the reduction of registered capital by the company's wholly-owned subsidiary
No Data
No Data